Evidence map›Paper›PMID 42583905›Full record

ArticleMedical care2026

Entrepreneurial Activity Among Independent Urology Groups.

Arnav Srivastava, Xiu Liu, Kassam S Faraj, Samuel R Kaufman, Avinash Maganty, Addison Shay, Mary Oerline, Paula Guro, Preeti Chachlani, Dawson Hill and 3 more

Abstract read
In one paragraph

Article in Medical care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Arnav SrivastavaDepartment of Urology, Dow Division of Health Services Research, University of Michigan, Ann Arbor, MI.ORCID 0000-0002-9772-1415
Xiu LiuDepartment of Urology, Massachusetts General Hospital, Boston, MA.
Kassam S FarajDepartment of Urology, Dow Division of Health Services Research, University of Michigan, Ann Arbor, MI.
Samuel R KaufmanDepartment of Urology, Dow Division of Health Services Research, University of Michigan, Ann Arbor, MI.
Avinash MagantyDepartment of Urology, Massachusetts General Hospital, Boston, MA.
Addison ShayDepartment of Urology, Dow Division of Health Services Research, University of Michigan, Ann Arbor, MI.
Mary OerlineDepartment of Urology, Dow Division of Health Services Research, University of Michigan, Ann Arbor, MI.
Paula GuroDepartment of Urology, Dow Division of Health Services Research, University of Michigan, Ann Arbor, MI.
Preeti ChachlaniDepartment of Urology, Massachusetts General Hospital, Boston, MA.
Dawson HillDepartment of Urology, Dow Division of Health Services Research, University of Michigan, Ann Arbor, MI.
Anqi SunDepartment of Urology, Dow Division of Health Services Research, University of Michigan, Ann Arbor, MI.
Vahakn B ShahinianDepartment of Urology, Dow Division of Health Services Research, University of Michigan, Ann Arbor, MI.
Brent K HollenbeckDepartment of Urology, Dow Division of Health Services Research, University of Michigan, Ann Arbor, MI.

Funding

Advanced Training in Urologic OncologyT32CA180984 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Ganesh S Palapattu, VAHAKN B SHAHINIAN · 2014 to 2026
$3.4M
Aligning financial incentives to promote rational use of active surveillance for prostate cancerR01CA269367 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BRENT K. HOLLENBECK, VAHAKN B SHAHINIAN · 2022 to 2026
$2.8M
Physician dispensing of oral specialty drugs for advanced prostate cancer and its implications for patientsR01CA275993 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HOLLENBECK, BRENT K., SHAHINIAN, VAHAKN B · 2023 to 2025
$2.5M
Accelerating the Shift to Downside Risk in Medicare Accountable Care Organizations: Effects on Clinical Quality and Costs among Older PatientsR01AG068074 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HOLLENBECK, BRENT K. · 2020 to 2024
$2.0M
Urology practice consolidation and care for men with prostate cancerR01CA279746 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BRENT K. HOLLENBECK, Andrew M Ryan · 2024 to 2026
$1.8M
NCI NIH HHS R01 CA269367NCI NIH HHS R01 CA275993NCI NIH HHS R01 CA279746NCI NIH HHS T32 CA180984NIA NIH HHS R01 AG068074
6 · The paper itself

Abstract

backgroundIndependent physician groups may develop novel revenue streams through ownership of services (eg, radiology equipment, ambulatory surgery centers), supplementing fee-for-service income. This form of entrepreneurial activity and its implied incentives for utilization may influence physician behavior and patient management. We developed an index measuring entrepreneurial activity of independent urology groups and assessed its association with diagnostic testing in men with benign prostatic hyperplasia (BPH).

methodsWe identified Traditional Medicare beneficiaries with BPH presenting to an independent urology group between 2017 and 2019. Using factor analysis of 9 unique ownership characteristics, we developed an index measuring entrepreneurial activity of independent urology groups (0-100-point scale). We assessed the relationship between the entrepreneurial index and 3 types of testing within 90 days of the initial new patient visit. At the patient level, we measured completion of a urinalysis (guideline-recommended), optional BPH testing (eg, ultrasound, cystoscopy), and testing unrelated to a BPH workup (ie, prostate-specific antigen, testosterone).

resultsThe urology group entrepreneurial index ranged from 0 to 97.2, with 20.6% (n=706/3430) of groups owning at least 1 ancillary service (ie, index >0). Among 49,285 men, an increasing entrepreneurial index (per 10-point increase) was associated with greater odds of undergoing a urinalysis (OR=1.13; 95% CI: 1.09-1.18; P<0.001), optional BPH tests (OR=1.05; 95% CI: 1.02-1.09; P=0.002), and testing unrelated to BPH (OR=1.21; 95% CI: 1.15-1.27; P<0.001).

conclusionsEntrepreneurial activity in urology, through ownership of ancillary services, is concentrated in a subset of groups. Among men presenting with BPH, the index was associated with increased guideline-recommended, optional, and unrelated testing.

Indexed as

benign prostatic hyperplasiaentrepreneurshipfinancial incentives

Identifiers

PMID42583905
PMCPMC13651501

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.